AMGN Q2 Deep Dive: Broad Portfolio Powers Guidance Upgrade, Pipeline Progress Remains Focus
Biotech company Amgen (NASDAQ:AMGN) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 9.5% year on year to $10.05 billion. The company’s full-year revenue guidance of $38.8 billion at the midpoint came in 2.8% above analysts’ estimates. Its non-GAAP profit of $6.29 per share was 12% above analysts’ consensus estimates.
Is now the time to buy AMGN? Find out in our full research report (it’s free for active Edge members).
Amgen (AMGN) Q2 CY2026 Highlights:
- Revenue: $10.05 billion vs analyst estimates of $9.40 billion (9.5% year-on-year growth, 6.9% beat)
- Adjusted EPS: $6.29 vs analyst estimates of $5.62 (12% beat)
- Adjusted Operating Income: $4.61 billion vs analyst estimates of $4.15 billion (45.9% margin, 11.1% beat)
- The company lifted its revenue guidance for the full year to $38.8 billion at the midpoint from $37.8 billion, a 2.6% increase
- Management raised its full-year Adjusted EPS guidance to $22.90 at the midpoint, a 2.2% increase
- Operating Margin: 35%, up from 28.9% in the same quarter last year
- Market Capitalization: $210.5 billion
StockStory’s Take
Amgen’s second quarter results reflected broad-based portfolio momentum, with management crediting double-digit growth in key products like Repatha, EVENITY, and TEZSPIRE for the company’s outperformance versus Wall Street estimates. CEO Robert Bradway highlighted that 22 products achieved double-digit sales growth, and 17 products annualized over $1 billion in sales, noting, “Our strong results were driven by the breadth and depth of our portfolio and once again demonstrate our ability to grow through patent expirations and increased competition.” Management also pointed to the performance of its biosimilars and innovative oncology franchises as important contributors this quarter.
Looking forward, Amgen’s updated guidance is shaped by continued investment in its late-stage pipeline and anticipated additional indications for existing products. Management emphasized the potential of upcoming data readouts for MariTide, Olpasiran, and Xaluritamig to drive future growth, while also acknowledging increased R&D spending and planned manufacturing expansion. CFO Peter Griffith stated, “Our commitment to investing in our business and enabling additional capacity supports our long-term growth well into the next decade,” highlighting ongoing capital expenditures and pipeline investments as central to sustaining future performance.
Key Insights from Management’s Remarks
Management attributed the strong quarterly performance to the expansion of high-growth products, disciplined R&D investment, and advances in late-stage clinical programs across multiple therapeutic areas.
- Key growth drivers excelled: Amgen’s six primary growth engines—Repatha, EVENITY, TEZSPIRE, Rare Disease, Innovative Oncology, and Biosimilars—collectively grew 26% year-over-year and now represent nearly 70% of product sales. This diversification helped offset headwinds from increased competition and loss of exclusivity in older products.
- Repatha and cardiovascular focus: Repatha delivered 37% revenue growth, driven by higher adoption for primary and secondary prevention of cardiovascular events, robust clinical evidence, and expanding prescriber base among primary care physicians, especially for diabetic patients. Management also highlighted broad payer access and ongoing global label expansion.
- Innovation in rare diseases: The rare disease portfolio grew 21%, underpinned by strong UPLIZNA sales and new indications. UPLIZNA’s efficacy in autoimmune conditions and convenient dosing led to rapid adoption, while new phase III studies seek to extend its reach to other diseases like autoimmune hepatitis and chronic inflammatory demyelinating polyneuropathy.
- Pipeline progress and AI integration: Late-stage assets MariTide (obesity), Olpasiran (cardiovascular risk), and Xaluritamig (oncology) advanced through key clinical milestones. Amgen is leveraging artificial intelligence to accelerate drug discovery and development, establishing a dedicated laboratory to combine proprietary human data with computational models.
- Manufacturing and operational scale-up: Capital investments in U.S. manufacturing sites are scaling up to support growth in high-demand products like MariTide, with management reaffirming a commitment to operational efficiency and global supply reliability.
Drivers of Future Performance
Amgen’s future performance will depend on the continued expansion of its core therapies, success in late-stage pipeline assets, and disciplined investment in manufacturing and R&D.
- Pipeline data readouts critical: Management identified upcoming Phase III results for MariTide (obesity and related diseases), Olpasiran (cardiovascular risk reduction), and Xaluritamig (oncology) as pivotal for shaping the company’s long-term growth. Positive data could unlock new treatment areas and expand the addressable market.
- Manufacturing capacity expansion: To support anticipated high demand for products like MariTide, Amgen is increasing capital expenditures and scaling manufacturing facilities in North Carolina, Ohio, and Puerto Rico. This infrastructure build-out aims to ensure reliable supply and accommodate volume growth for upcoming product launches.
- Investment in AI and operational efficiency: The company is integrating artificial intelligence across discovery, development, and manufacturing. Management believes these initiatives will accelerate drug development timelines, improve clinical trial execution, and enhance the scalability of its biologics portfolio, although execution risks and regulatory uncertainties remain.
Catalysts in Upcoming Quarters
Our analysts will be watching (1) the pace and outcome of pivotal clinical trial readouts for MariTide, Olpasiran, and Xaluritamig, (2) the impact of expanded manufacturing capacity on supply reliability and launch execution for new therapies, and (3) the continued uptake and payer access for core growth drivers like Repatha, EVENITY, and TEZSPIRE. Progress on AI integration and business development activity will also be key markers of Amgen’s execution.
Amgen currently trades at $389.92, in line with $390.02 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.